슬로바키아 -
슬로바키아어 -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
vinorelbine glenmark 20 mg
glenmark pharmaceuticals s.r.o., Česká republika - vinorelbín - 44 - cytostatica
슬로바키아 -
슬로바키아어 -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
ondansetron kalceks 2 mg/ml injekčný/infúzny roztok
as kalceks, lotyšsko - ondansetrón - 20 - antiemetica, antivertiginosa
슬로바키아 -
슬로바키아어 -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
ondansetron kabi 0,16 mg/ml
fresenius kabi deutschland gmbh, nemecko - ondansetrón - 20 - antiemetica, antivertiginosa
슬로바키아 -
슬로바키아어 -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
ondansetron kabi 0,08 mg/ml
fresenius kabi deutschland gmbh, nemecko - ondansetrón - 20 - antiemetica, antivertiginosa
슬로바키아 -
슬로바키아어 -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
vinorelbine medac 80 mg mäkké kapsuly
medac gesellschaft für klinische spezialpräparate m.b.h., nemecko - vinorelbín - 44 - cytostatica
슬로바키아 -
슬로바키아어 -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
vinorelbine medac 30 mg mäkké kapsuly
medac gesellschaft für klinische spezialpräparate m.b.h., nemecko - vinorelbín - 44 - cytostatica
슬로바키아 -
슬로바키아어 -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
vinorelbine medac 20 mg mäkké kapsuly
medac gesellschaft für klinische spezialpräparate m.b.h., nemecko - vinorelbín - 44 - cytostatica
유럽 연합 -
슬로바키아어 -
EMA (European Medicines Agency)
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastické činidlá - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.